NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · MID CAP
Cytek Biosciences, Inc. CTKB
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$201.5M
▲ 0.5% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-18.0%
Net margin · FY25
-33.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 201.5M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 33 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-18.0%
Return on equity, FY2025
ROE
Operating margin-20.0%
Net margin-33.0%
Return on assets-13.8%
Each USD of equity lost 18 cents this year.
Returned to shareholders
USD 14.7M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 14.7M
Share of profit-22.2%
Consecutive raises—
USD 14.7M in buybacks went back to shareholders in a year without profit.
Growth
+16.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+7.1%
+16.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.13B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 461.5M
total assets, end of FY2025
Total assetsUSD 461.5M
EquityUSD 341.7M
CashUSD 90.9M
Current ratio5.04×
Equity funds 74% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.2
0.2
0.2
0.2
0.1
0.1
Operating income $B
−0.0
−0.0
−0.0
−0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
−0.0
−0.0
0.0
−0.0
Net income $B
−0.1
−0.0
−0.0
0.0
0.0
0.0
EPS, diluted $
·
·
−0.09
0.02
0.00
0.10
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−18.0
−1.5
−3.0
0.6
1.6
·
Shares out B
0.13
0.13
0.13
0.14
0.13
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed